CTEV vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CTEV exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -2.27, indicating negative shareholder equity. While the company maintains strong gross margins (73.75%) and a low Price-to-Sales ratio (0.42), these are overshadowed by catastrophic earnings volatility and a 5-year price collapse of 91.9%. The current liquidity position is precarious with a current ratio of 0.86, suggesting an inability to cover short-term obligations. Despite bullish analyst targets, the deterministic data points to a high-risk value trap.
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Compare Another Pair
Related Comparisons
CTEV vs JNJ: Head-to-Head Comparison
This page compares Claritev Corporation (CTEV) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.